Every 424B that Sotera Health Company (SHC) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow SHC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SHC filings page.
Sotera Health Company resale offering: 31,838,253 shares of common stock are being offered by selling stockholders pursuant to this prospectus supplement. The company will not receive proceeds from these sales; proceeds will go to the selling stockholders.
The shares are being offered at a public offering price of $15.27 per share, with underwriting discounts of $0.102 per share. Delivery is expected on or about May 13, 2026. The Sponsors (affiliates of Warburg Pincus and GTCR) are expected to hold no remaining shares and will cease to have the related governance rights described in the offering materials following completion of this offering. Shares outstanding were 285,166,994 as of April 28, 2026.
Sotera Health Company is registering the resale of 31,838,253 shares of common stock by selling stockholders pursuant to a preliminary prospectus supplement dated May 11, 2026. The company will not receive any proceeds from the sales; proceeds will go to the selling stockholders.
The prospectus supplement states the selling stockholders include investment funds and affiliates of Warburg Pincus and GTCR, and that, following this offering, the Sponsors are not expected to hold any remaining shares or retain prior governance designation rights. The filing cites 285,166,994 shares outstanding as of April 28, 2026 and discloses a last reported sale price of $15.78 per share (May 8, 2026).
Sotera Health Company is registering 25,000,000 shares for resale by selling stockholders. The prospectus supplement states the underwriter has agreed to purchase the shares from the selling stockholders at $15.27 per share, which would yield $381,750,000 to those selling stockholders before expenses, and the Company will not receive proceeds from these sales.
The supplement lists delivery expected on March 6, 2026, notes a Nasdaq last reported sale price of $15.76 per share on March 4, 2026, and describes the underwriter’s ability to sell the shares on Nasdaq, OTC markets or through negotiated transactions.
Sotera Health Company discloses a resale offering by certain selling stockholders pursuant to a preliminary prospectus supplement dated March 4, 2026.
The company states it is not selling any shares in this filing and will receive no proceeds from the shares sold by the selling stockholders; proceeds will go to those selling holders. The prospectus cites 284,392,079 shares outstanding as of February 17, 2026 and a last reported Nasdaq sale price of $15.76 per share on March 4, 2026.
Sotera Health Company (SHC) announced a secondary offering in which the selling stockholders are offering 30,000,000 shares of common stock. The Company is not selling shares and will not receive proceeds. The offering price is $15.70 per share, the underwriting discount is $0.049 per share, and proceeds to selling stockholders are $469,530,000 before expenses. Delivery of shares is expected on or about November 10, 2025, with Goldman Sachs & Co. LLC as underwriter.
Including Warburg Pincus affiliates 18,000,000 shares and GTCR affiliates 12,000,000 shares. Shares outstanding were 284,093,929 as of October 28, 2025. The Company and insiders agreed to 30‑day lock-up provisions, subject to customary exceptions. SHC’s common stock trades on Nasdaq under the symbol SHC; the last reported price on November 6, 2025 was $16.01 per share.
Sotera Health Company filed a preliminary prospectus supplement for a secondary sale of common stock by selling stockholders. The company states it is not selling any shares in this transaction and will not receive any proceeds from the sales.
The common stock trades on Nasdaq under the symbol SHC; the last reported sale price was $16.01 on November 6, 2025. As context, 284,093,929 shares were outstanding as of October 28, 2025. Goldman Sachs & Co. LLC is acting as underwriter, and standard 30‑day lock-up agreements apply to the company, executive officers, directors, and the selling stockholders, subject to stated exceptions.
The document highlights typical offering risks, potential market volatility, and notes that future issuances or sales could affect the trading price of SHC. Investors are directed to the “Risk Factors” section in this supplement and incorporated filings for additional details.